{"id":"fmx-101-4-minocycline-foam","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Minocycline is a broad-spectrum tetracycline antibiotic that works through multiple mechanisms in acne treatment: it inhibits bacterial protein synthesis to reduce Cutibacterium acnes (formerly Propionibacterium acnes) proliferation, and it also has anti-inflammatory properties that suppress cytokine production and neutrophil activation independent of its antimicrobial effects. The 4% foam formulation provides topical delivery to affected skin areas while minimizing systemic absorption.","oneSentence":"Minocycline, a tetracycline antibiotic, reduces inflammation and bacterial colonization in acne by inhibiting bacterial protein synthesis and suppressing inflammatory mediators.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:12.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT04960930","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne Vulgaris","status":"COMPLETED","sponsor":"Cutia Therapeutics (Shanghai) Co., Ltd","startDate":"2021-09-17","conditions":"Acne Vulgaris","enrollment":372},{"nctId":"NCT04940767","phase":"PHASE4","title":"A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Edward Lain, MD","startDate":"2021-06-28","conditions":"Acne Vulgaris","enrollment":31},{"nctId":"NCT02815267","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2016-05","conditions":"Acne Vulgaris","enrollment":466},{"nctId":"NCT03271021","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-07-17","conditions":"Acne Vulgaris","enrollment":1488},{"nctId":"NCT02815280","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2016-05","conditions":"Acne Vulgaris","enrollment":495},{"nctId":"NCT02250859","phase":"PHASE1","title":"A Pharmacokinetic Study of Minocycline in Male and Female Volunteers","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2014-09","conditions":"Acne","enrollment":12},{"nctId":"NCT01134991","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients","status":"TERMINATED","sponsor":"Vyne Therapeutics Inc.","startDate":"2010-06","conditions":"Rosacea","enrollment":21},{"nctId":"NCT01171326","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2010-08","conditions":"Impetigo","enrollment":32},{"nctId":"NCT01362010","phase":"PHASE2","title":"Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2012-01","conditions":"Acne Vulgaris","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FMX-101, 4% minocycline foam","genericName":"FMX-101, 4% minocycline foam","companyName":"Vyne Therapeutics Inc.","companyId":"vyne-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Minocycline, a tetracycline antibiotic, reduces inflammation and bacterial colonization in acne by inhibiting bacterial protein synthesis and suppressing inflammatory mediators. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}